Noxafil (posaconazole)

Midostaurin clearance was delayed during co-administration. Midostaurin therapeutic drug monitoring may serve for decision-making when DDI with CYP3A4 inhibitors is suspected.

P3, N=664, Not yet recruiting, University of Minnesota | Initiation date: May 2026 --> Sep 2026

P1/2, N=84, Recruiting, AstraZeneca

In multivariable analysis, patients who received azole AFP did not have improved survival (HR 1.29, 95% CI 1.10-1.53, P = .004) compared to patients who did not (median OS 10 months vs. 11 months), with similar lack of benefit across agents: voriconazole (HR 1.04, p = 0.75), fluconazole (HR 1.26, p = 0.039), isavuconazole (1.52, p = 0.048), and posaconazole (HR 1.62, p = 0.005). Routine azole AFP does not improve overall survival in patients receiving Ven/HMA, contrasting with proven benefits in intensive chemotherapy, likely due to lower fungal infection risk combined with the complexities of managing drug-drug interactions in routine practice, as evidenced by high rates of inadequate venetoclax dose adjustment in this cohort.

The trough concentrations of venetoclax were 9326.88 ± 12,169.05 ng/mL in patients treated with venetoclax alone, and 31,623.55 ± 28,453.67 ng/mL in patients treated with venetoclax in combination with posaconazole. A rapid and simple method was established and successfully applied to the simultaneous determination of the concentrations of venetoclax and posaconazole in AML patients, providing a basis for TDM and clinical pharmacokinetic analysis of these drugs in AML patients.

P3, N=602, Completed, Mundipharma Research Limited | Active, not recruiting --> Completed

P3, N=602, Active, not recruiting, Mundipharma Research Limited | Completed --> Active, not recruiting

P2, N=72, Recruiting, Shandong Cancer Hospital and Institute | N=20 --> 72

Furthermore, flow cytometry and colony formation assays revealed that PCZ attenuates and reduces the apoptotic/necrotic effects of ATO. In conclusion, PCZ synergistically and effectively reduces the adverse cytotoxic effects of ATO in lung cancer cells, providing a promising new therapeutic strategy for lung cancer treatment.

P=N/A, N=360, Completed, Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting --> Completed

P3, N=602, Active, not recruiting, Mundipharma Research Limited | Recruiting --> Active, not recruiting

P=N/A, N=200, Not yet recruiting, Shanghai General Hospital; Shanghai General Hospital